Radiosensitizing Compound Scheduling for Tumor Volume Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing radiation treatments for cancer, including those using sulfoquinovosylacylpropanediol, fail to effectively stop the increase in tumor volume despite reducing it, necessitating improved radiosensitizing agents to enhance therapeutic outcomes.

Innovation Solution

Administer a compound represented by General Formula (I) or its pharmaceutically acceptable salt at a dose of 8 mg/kg or less, followed by immediate radiation therapy with a dosage of 10 Gy or more, repeating this set at appropriate intervals to enhance radiation treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional radiation treatment is used, then some tumor reduction is achieved, but the increase in tumor volume cannot be effectively stopped

Engineering Contradiction:

Improvetherapeutic effectVSAvoidtumor volume control

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the chemical structure parameters of the radiosensitizing agent by using sulfoquinovosylacylpropanediol compounds with specific acyl residues (fatty acid chains of varying lengths and saturation levels). This structural modification enhances the compound's ability to sensitize tumor cells to radiation, thereby improving both therapeutic effect and tumor volume control compared to conventional agents

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention combines the sulfoquinovosyl core structure with various fatty acid acyl residues to create a series of composite compounds. These composite structures allow optimization of both water solubility and membrane permeability, enhancing the radiosensitizing effect while controlling tumor growth more effectively than single-structure agents

Inventive Principle:

Principle #40Composite materials

2Reliability

If high radiation dosage is administered, then tumor control improves, but side effects increase

Engineering Contradiction:

Improvetumor controlVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The sulfoquinovosylacylpropanediol compound acts as an intermediary substance that amplifies the effect of radiation on tumor cells. By administering this radiosensitizing agent, the same radiation dosage produces enhanced tumor cell damage, allowing effective tumor control at lower or moderate radiation doses, thereby reducing side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The radiosensitizing agent exhibits selective accumulation in tumor tissues due to the enhanced permeability and retention effect characteristic of tumor vasculature. This local concentration of the compound enhances radiation sensitivity specifically in tumor cells while sparing normal tissues, thus improving tumor control without proportionally increasing systemic side effects

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12440505B2Method of treating cancer

Publication Date: 2025.10.14 M T 3 INC

AI summary

There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.